Author:

JA Vazquez, MT Arganoza, D Boikov, JK Vaishampayan & RA Akins

Date: 4 April 2004

Abstract:

Candidaspecies are an important cause of opportunistic infection in the oralcavity of immunocompromised patients, especially HIV infected patients.Melaleuca oil obtained commercially was investigated since it is known to havebroad antifungal properties. The in-vitro susceptibilities of Aspergillus and susceptibleand resistant Candidaspecies were performed utilizing serial dilutions inmicrotiter plates with Sabouraud dextrose agar and the commercial preparationof Melaleuca. As a comparator, in vitrosusceptibilities to amphotericin B and fluconazolewere also determined using the broth microdilution technique. Theresults demonstrate that Melaleucainhibited the Candida species. However, thegrowth of Aspergilluswas not inhibited at the concentrations tested. Thus, preparationscontaining Melaleuca alternafolia may be a useful alternative for superficialcandidal infections. In fact, it may be a useful alternative regimen foradvanced HIV-positive patients with oropharyngeal candidiasis refractory to fluconazole.However, controlled clinical studies to evaluate its efficacy are still needed.

Link to DOI

Download the full article (Disclaimer)

This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.

I understand (click to accept and view download link)

---